The role of probiotics in inflammatory bowel disease

Digestive Diseases and Sciences

Volumn 52, Issue 3, 2007, Pages 607-611

  Jones, Jennifer L ^a   Foxx Orenstein, Amy E ^a  

^a MAYO CLINIC   (United States)

Author keywords

Bacteria; Crohn's disease; Inflammatory bowel disease; Probiotics; Review; Ulcerative colitis

Indexed keywords

MESALAZINE; PROBIOTIC AGENT;

ANTIINFLAMMATORY ACTIVITY; BACTERIAL VIRULENCE; BIFIDOBACTERIUM; BLOATING; CLINICAL TRIAL; CLOSTRIDIUM BUTYRICUM; CONSTIPATION; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG WITHDRAWAL; ENTERITIS; ESCHERICHIA COLI; HEMATOCHEZIA; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; INTESTINE FLORA; LACTOBACILLUS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SACCHAROMYCES; STREPTOCOCCUS THERMOPHILUS; ULCERATIVE COLITIS;

ANIMALS; BIFIDOBACTERIUM; CROHN DISEASE; HUMANS; LACTOBACILLUS; POUCHITIS; PROBIOTICS;

EID: 33847215148     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-9225-y     Document Type: Review

References (48)

1. Guarner F, Malagelada J (2003) Gut flora in health and disease.[see comment]. Lancet 361:512-519
2. Sartor R (2004) Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 126:1620-1633
3. Guarner F, Shaafsma G (1998) Probiotics. Int J Food Microbiol 39:237-238
4. Fioramonti J, Theodorou V, Bueno L (2003) Probiotics: what are they? What are their effects on gut physiology? Best Pract Res Clin Gastroenterol 17:711-724
5. Sartor R (2005) Probiotic therapy of intestinal inflammation and infections. Curr Opin Gastroenterol 21:44-50
6. Donohue D, Salminen S, Marteau P (1998) Safety of probiotic bacteria. In: Salminen S, Von Wright A (eds) Lactic acid bacteria. New York, Marcel Decker, pp 369-384
7. Farina C, Arosio M, Mangia M, Moioli F (2001) Lactobacillus casei subsp. rhamnosus sepsis in a patient with ulcerative colitis. J Clin Gastroenterol 33:251-252
8. Pletinex M, Legein J, Vandeplas Y (1995) Fungicemia with Saccharomyces boulardii in a 1- year old girl with protracted diarrhea. J Pediatr Gastroenterol Nutr 21:113-115
9. Fedorak R, Madsen K (2004) Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis 10:286-299
10. Riquelme A, Calvo M, Guzman A, Depix M, Garcia P, Perez C, et al. (2003) Saccharomyses cerevaciae fungemia after Saccharomyses boulardii treatment in immunocompromised patients. J Clin Gastroenterol 36:41-43
11. Rautio M, Jousimies-Somer H, Kauma H, Pietarinen I, Saxelin M, Tynkkynen S, et al. (1999) Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 28:1159-1160
12. Hennequin C, Kauffmann-Lacroix C, Jobert A, Viard J, Ricour C, Jacquemin J, et al. (2000) Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis 19:16-20
13. Tamboli C, Caucheteux C, Cortot A, Colombel J, Desreumaux P (2003) Probiotics in inflammatory bowel disease: a critical review. Best Pract Res Clin Gastroenterol 17:805-820
14. Salminen M, Tynkkynen S, Rautelin H, Saxelin M, Vaara M, Ruutu P, et al. (2002) Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis 35:1155-1160
15. Hamilton-Miller J, Shah S, Winkler J (1999) Public health issues arising from microbiological and labelling quality foods and supplements containing probiotic organisms. Public Health Nutr 2:223-229
16. Katz J, Pirovano F, Matteuzzi DEA (2002) Commercially available probiotic preparations: are you getting what you pay for? Gastroenterology 122:A459
17. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, zum Meyer Buschenfelde K (1995) Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) [see comment]. Clin Exp Immunol 102:448-455
18. Macpherson A, Khoo U, Forgacs I, Philpott-Howard J, Bjarnason I (1996) Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 38:365-375
19. Sartor R (2003) Microbial influences in inflammatory bowel disease: role in pathogenesis and clinical implications. In: Sartor R, Sandborn W, eds. Kirsner's Inflammatory Bowel Diseases. 6 ed. Edinburgh, Elsevier, pp 138-162
20. Neut C, Bulois P, Desreumaux P, Membre J, Lederman E, Gambiez L, et al. (2002) Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. Am J Gastroenterol 97:939-946
21. Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, et al. (2002) Mucosal flora in inflammatory bowel disease. Gastroenterology 122:44-54
22. Cartun R, Van Kruiningen H, Pedersen C, Berman M (1993) An immunocytochemical search for infectious agents in Crohn's disease. Modern Pathol 6:212-219
23. Shanahan F (2000) Probiotics and inflammatory bowel disease: Is there a scientific rationale? Inflamm Bowel Dis 6:107-115
24. D'Haens G, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P (1998) Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 114:262-267
25. Rutgeerts P, Van Assche G, Vermeire S, D'Haens G, Baert F, Noman M, et al. (2005) Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 128:856-861
26. Cario E (2005) Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut 54:1182-1193
27. Buning C, Genschel J, Buhner S, Kruger S, Kling K, Dignass A, et al. (2004) Mutations in the NOD2/CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation. Aliment Pharmacol Ther 19:1073-1078
28. Cobrin G, Abreu M (2005) Defects in mucosal immunity leading to Crohn's disease. Immunol Rev 206:277-295
29. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, et al. (2000) Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289:1352-1355
30. Prantera C, Scribano M, Falasco G, Andreoli A, Luzi C (2002) Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 51:405-409
31. Malchow H (1997) Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 25:653-658
32. Guslandi M, Mezzi G, Sorghi M, Testoni P (2000) Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 45:1462-1464
33. Ingrassia I, Leplingard A, Darfeuille-Michaud A (2005) Lactobacillus casei DN-114 001 inhibits the ability of adherent-invasive Escherichia coli isolated from Crohn's disease to and to invade intestinal epithelial cells. Appl Environ Microbiol 71:2880-2887
34. Braat H, van den Brande J, van Tol E, Hommes D, Peppelenbosch M, van Deventer S (2004) Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function. Am J Clin Nutr 80:1618-1625
35. Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, et al. (1999) Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 13:1103-1108
36. Rembacken B, Snelling A, Hawkey P, Chalmers D, Axon A (1999) Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354(9179):635-639
37. Kruis W, Kalk E, Fric P, et al. (2001) Maintenance of remission in ulcerative colitis is equally effective with Escherichia coli Nissle 1917 and with standard mesalamine. Gastroenterology 120:A127
38. Schroeder K, Tremaine W, Ilstrup DM (1987) Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis-a randomized study. N Engl J Med 317:1625-1629
39. Baron J, Connell A, Lennard-Jones J (1964) Variation in observers in describing mucosal appearances in proctocolitis. BMJ i:89-92
40. Fedorak R, Gionchetti P, Campieri M (2003) VSL3 probiotic mixture induces remission in patients with active ulcerative colitis (abstr). Gastroenterology 124:A377
41. Guslandi M, Giollo P, Testoni P (2003) A pilot trial of saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 15:697-698
42. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, et al. (2000) Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119:305-309
43. Mimura T, Rizzello F, Schreiber S, et al. (2002) Once daily high dose probiotic therapy maintains remission and improved quality of life in patients with recurrent or refractory pouchitis: a randomized, placebo-controlled, double-blind trial. Gastroenterology 122:A81
44. Sandborn W, Tremaine W, Batts K, Pemberton J, Phillips S (1994) Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin Proc 69:409-415
45. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers K, Brigidi P, et al. (2003) Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124:1202-1209
46. Shen B, Fazio V, Remzi F, et al. (2005) An open-labeled trial of probiotic as a maintenance therapy in patients with antibiotic-dependent pouchitis. Gastroenterology 124:A586
47. Heuschen U, Autschbach F, Allemeyer E, Zollinger A, Heuschen G, Uehlein T, et al. (2001) Long-term follow-up after ileoanal pouch procedure: algorithm for diagnosis, classification, and management of pouchitis. Dis Colon Rectum 44:487-499
48. Shen B, Achkar J, Lashner B, Ormsby A, Remzi F, Bevins C, et al. (2001) Endoscopic and histologic evaluation together with symptom assessment are required to diagnose pouchitis. Gastroenterology 121:261-267